Targeting IL-6 trans-signalling: past, present and future prospects
S Rose-John, BJ Jenkins, C Garbers, JM Moll… - Nature Reviews …, 2023 - nature.com
Abstract Interleukin-6 (IL-6) is a key immunomodulatory cytokine that affects the
pathogenesis of diverse diseases, including autoimmune diseases, chronic inflammatory …
pathogenesis of diverse diseases, including autoimmune diseases, chronic inflammatory …
KRAS mutation: from undruggable to druggable in cancer
L Huang, Z Guo, F Wang, L Fu - Signal transduction and targeted …, 2021 - nature.com
Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …
Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment
Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …
IL-6 in inflammation, autoimmunity and cancer
T Hirano - International immunology, 2021 - academic.oup.com
IL-6 is involved both in immune responses and in inflammation, hematopoiesis, bone
metabolism and embryonic development. IL-6 plays roles in chronic inflammation (closely …
metabolism and embryonic development. IL-6 plays roles in chronic inflammation (closely …
Cell death in pancreatic cancer: from pathogenesis to therapy
Pancreatic cancer is a devastating gastrointestinal cancer characterized by late diagnosis,
limited treatment success and dismal prognosis. Exocrine tumours account for 95% of …
limited treatment success and dismal prognosis. Exocrine tumours account for 95% of …
Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer
The tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) involves a
significant accumulation of fibroblasts as part of the host response to cancer. Using single …
significant accumulation of fibroblasts as part of the host response to cancer. Using single …
The tumour microenvironment in pancreatic cancer—clinical challenges and opportunities
WJ Ho, EM Jaffee, L Zheng - Nature reviews Clinical oncology, 2020 - nature.com
Metastatic pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumours
despite the use of multi-agent conventional chemotherapy regimens. Such poor outcomes …
despite the use of multi-agent conventional chemotherapy regimens. Such poor outcomes …
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
L Buscail, B Bournet, P Cordelier - Nature reviews Gastroenterology & …, 2020 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second most common
cause of death within the next 10 years. The prognosis for this disease is poor despite …
cause of death within the next 10 years. The prognosis for this disease is poor despite …
Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis
INTRODUCTION The association between tumors and inflammation is a long-established
clinical observation. Although many studies have demonstrated that the inflammatory …
clinical observation. Although many studies have demonstrated that the inflammatory …
Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most
difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream …
difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream …